clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT03882034 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | United States of America | Q30 |
P582 | end time | 2022-01-01 | |
P4135 | maximum age | 18 | |
P1050 | medical condition | acromegaly | Q189580 |
P2899 | minimum age | 2 | |
P1132 | number of participants | 60 | |
P859 | sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development | Q5409765 |
P580 | start time | 2019-03-27 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess |
Search more.